The British Medical Association opened its ballot of partners in England yesterday over the move that would involve them limiting the number of patients they see
Generative Artificial Intelligence (Gen AI) can rapidly and accurately screen patients for clinical trial eligibility, according to a new study from Mass General Brigham researchers. Such technology could make it faster and cheaper to…
At this point of the offseason, it's difficult to find plug-and-play starters on the open market, but one former NFL Defensive Player of the Year is the exception.
Figures come amid record dissatisfaction with GPs and long waits for diagnostic tests, with patients often struggling to be seen. Cancer Research UK described the situation as 'unacceptable'.
Hospital worker Mohammad Farooq, 28, allegedly planned to "kill as many nurses as possible" when he was arrested with a pressure cooker bomb outside St James's Hospital in Leeds
In response to the recent outcry over an abandoned patient found in a bush near Gomoa Ojobi, the Medical Director of Trauma and Specialist Hospital, Winneba, Dr. Prah George Kwame has clarified that the patient was declared well and…
Early in the pandemic, many people who had SARS-CoV-2 infection or COVID-19 began to report that they couldn't shake off their symptoms even after a month or more—unusually long for a viral infection of the upper respiratory tract—or…
Although the FDA has determined lecanemab's benefits outweigh its risks in treating Alzheimer's, the CMS is pressing for more data on its efficacy and safety.
It's welcome news for Alzheimer's patients and their families: A Food and Drug Administration advisory panel unanimously recommended approval for Eli Lilly & Co.'s treatment donanemab. If given the agency's green light later this year, it…
The physio was branded a "danger to women" by one investigating officer who said "depraved" Bawa "belongs behind bars" after the court heard he took advantage of seven women
Monday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced topline results from the Phase 3 RAISE trial evaluating the safety and efficacy of intravenous (IV) ganaxolone for refractory status epilepticus (RSE).